VaxGen’s Manufacturing Capability

• 48,000 sq. ft. manufacturing facility

  • 1,000-liter bioreactor
  • 200-liter bioreactor
  • Pilot and commercial capability

• rPA - cGMP bulk production to start Q4 ’03

• Flexible, multi-product biologics manufacturing

  • Anthrax vaccine
  • Other bacterial
  • Mammalian cell culture

South San Francisco Facility

Previous slide

Next slide

Back to first slide

View graphic version